Atara Biotherapeutics (ATRA) Interest Expenses (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Interest Expenses came in at $830000.0 in Q1 2026, down 79.95% YoY from $4.1 million in Q1 2025, and up 3508.7% on a QoQ basis from $23000.0 in Q4 2025.
Atara Biotherapeutics (ATRA) Interest Expenses (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Interest Expenses data on file, last reported at $830000.0 in Q1 2026.
- Quarterly Interest Expenses fell 79.95% year-over-year to $830000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.3 million (down 4.04% YoY) and the FY2025 annual result came in at $355.0 million, up 2116.39% from the prior year.
- Interest Expenses grew to $830000.0 in Q1 2026, from $23000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $96.0 million in Q3 2022 to a low of $23000.0 in Q4 2025.
- A 5-year average of $10.5 million and a median of $1.4 million in 2023 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 1834.15% in 2025, down 99.44% in 2025.
- Tracing ATRA's Interest Expenses over 5 years: stood at $13.2 million in 2022, then plunged by 91.06% to $1.2 million in 2023, then jumped by 250.17% to $4.1 million in 2024, then slumped by 99.44% to $23000.0 in 2025, then soared by 3508.7% to $830000.0 in 2026.
- The last three Interest Expenses figures came in at $830000.0 (Q1 2026), $23000.0 (Q4 2025), and $6.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.77 Bn | 131.91 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 65.36 Bn | 60.17 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.60 Bn | 54.47 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 93.62 Mn |
| 10 | Atara Biotherapeutics | 144.47 Mn | 127.92 Mn | 439,000.00 | 191,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.04 Mn |
| Jun 30, 2026 | 13.04 Mn |
| Mar 31, 2026 | 830,000.00 |
| Mar 31, 2026 | 830,000.00 |
| Dec 31, 2025 | 23,000.00 |
| Dec 31, 2025 | 23,000.00 |
| Sep 30, 2025 | 6.32 Mn |
| Sep 30, 2025 | 6.32 Mn |
| Jun 30, 2025 | 24.41 Mn |
| Jun 30, 2025 | 24.41 Mn |
| Mar 31, 2025 | 4.14 Mn |
| Mar 31, 2025 | 4.14 Mn |
| Dec 31, 2024 | 4.12 Mn |
| Dec 31, 2024 | 4.12 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Mar 31, 2024 | 3.99 Mn |
| Mar 31, 2024 | 3.99 Mn |